STOCK TITAN

Accuray Incorporated - $ARAY STOCK NEWS

Welcome to our dedicated page for Accuray Incorporated news (Ticker: $ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorporated stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Accuray Incorporated's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Accuray Incorporated's position in the market.

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) reported a decrease in net revenue for the third quarter and nine-months ended March 31, 2024. The GAAP net loss was $6.3 million, with gross orders increasing by 21%. Despite challenges, the company remains confident in its growth strategy and ability to offer value globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.03%
Tags
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) is showcasing advances in radiation therapy solutions at ESTRO 2024, celebrating 30 years of innovation. The latest CyberKnife® and Radixact® platforms improve cancer treatment, expanding curative power and bridging care gaps. Accuray prioritizes patient well-being with precise technologies. Technologies highlighted include the Radixact System with enhanced imaging capabilities, ClearRT™, CyberComm™ for faster patient treatment, and Cenos™ for adaptive treatment planning. The company's legacy includes breakthroughs in cancer and neuro-radiosurgical technology, driving personalized patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) expands its global training center network by opening a new facility in Genolier, Switzerland. The center aims to advance patient care through education on the Accuray CyberKnife® and Radixact® Systems. The facility offers hands-on simulation, seminars, and workshops for medical professionals involved in radiotherapy and radiosurgery. The partnership with Genolier Innovation Hub enhances access to high-quality training and innovative techniques.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024 on May 1, 2024. The conference call will be hosted by company management at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call through dial-in numbers or a live webcast on the company's Investor Relations website. A replay will be available for one week after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences earnings
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) presented new data at the 2024 Radiosurgery Society Meeting supporting the use of the CyberKnife System in treating high-risk and recurrent prostate cancer. The system's precision with stereotactic body radiation therapy (SBRT) offers effective treatment in 4-5 sessions compared to traditional therapy. The data highlighted favorable outcomes, low toxicities, and the system's ability to track and correct for prostate movement during treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
-
Rhea-AI Summary
Accuray Incorporated (ARAY) will participate in the 36th Annual Roth Conference with a fireside chat on March 18, 2024. The event will be live webcasted and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
conferences
Rhea-AI Summary
Accuray Incorporated (ARAY) will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12-13, 2024. The management team will engage in a fireside chat on March 12, 2024, at 7:00am PST / 10:00am EST. Investors can access the live webcast on the Accuray website with a replay available post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) partners with Montérégie Integrated Cancer Center to introduce Radixact System for cancer treatment in Quebec. The system includes ClearRT™ and Synchrony® technologies to enhance treatment outcomes and minimize side effects. The center aims to set a new standard in precision and accuracy for radiation therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) is set to participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024. The event is exclusive to BTIG clients, offering the opportunity for one-on-one meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.4%
Tags
conferences
Rhea-AI Summary
Accuray Incorporated (NASDAQ: ARAY) reported a 19% increase in gross orders, 8% service revenue expansion, and confirmed FY24 guidance. Net revenue for the second quarter of fiscal 2024 was $107.2 million, a 3% sequential increase and a 7% decrease from the same period in the prior fiscal year. GAAP net loss was $9.6 million, compared to $1.9 million in the prior fiscal year. Adjusted EBITDA was $2.0 million, compared to $8.5 million in the same period in the prior fiscal year. The company also reported a 6% increase in gross orders for the first six months of fiscal 2024 and reaffirmed guidance for fiscal year 2024, expecting total revenue in the range of $460 million to $470 million, representing a year-over-year growth range of 3 to 5 percent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
Accuray Incorporated

Nasdaq:ARAY

ARAY Rankings

ARAY Stock Data

165.61M
88.53M
3.58%
66.36%
5.31%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
MADISON

About ARAY

accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.